BCSCDB: Biomarkers of Cancer Stem Cells Database
Number of entries related to PANC-1 cell line is 942
| GENE | HGNC_ID | MARKER_TYPE | CANCER_TYPE | HISTOLOGICAL_TYPE | CELL_LINE | CSC_ENRICHMENT | METHOD | EXPRESSION_LEVEL | CONFIDENCE_SCORING | GLOBAL_SCORING | PUBMED_ID |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NANOG | 20857 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and qRT-PCR followed by Western Blotting and IF staining | NA | 0.72 | 0.5461 | 29975934 |
| NANOG | 20857 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | Gemcitabine | SFA followed by qRT-PCR and Western Blotting | NA | 0.72 | 0.5461 | 35158144 |
| NANOG | 20857 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | Gemcitabine | qRT-PCR followed by Western Blotting | NA | 0.72 | 0.5461 | 28703793 |
| NANOG | 20857 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.72 | 0.5461 | 27996162 |
| NANOG | 20857 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.72 | 0.5461 | 29937934 |
| NANOG | 20857 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | Gemcitabine | SFA followed by qRT-PCR and Western Blotting | NA | 0.72 | 0.5461 | 31508487 |
| NANOG | 20857 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by RT-PCR and Western Blotting | NA | 0.72 | 0.5461 | 23872274 |
| NANOG | 20857 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SP assay followed by qRT-PCR and Western Blotting | NA | 0.72 | 0.5461 | 24040121 |
| NANOG | 20857 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | FACs followed by SFA and qPCR | NA | 0.72 | 0.5461 | 30954649 |
| NANOG | 20857 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and Western Blotting | NA | 0.72 | 0.5461 | 35428310 |
| NANOG | 20857 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Western Blotting | NA | 0.72 | 0.5461 | 33115754 |
| NANOG | 20857 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Western Blotting | NA | 0.72 | 0.5461 | 34551785 |
| NANOG | 20857 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Western Blotting | NA | 0.72 | 0.5461 | 26458814 |
| NANOG | 20857 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | Gemcitabine | SFA followed by Western Blotting | NA | 0.72 | 0.5461 | 30341797 |
| NANOG | 20857 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | Gemcitabine | SFA followed by Western Blotting | NA | 0.72 | 0.5461 | 30341797 |
| NANOG | 20857 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Western Blotting | NA | 0.72 | 0.5461 | 30535490 |
| NANOG | 20857 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Western Blotting | NA | 0.72 | 0.5461 | 32766132 |
| NANOG | 20857 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | Western Blotting | NA | 0.72 | 0.5461 | 29179494 |
| NANOG | 20857 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | Western Blotting | NA | 0.72 | 0.5461 | 29947365 |
| NANOG | 20857 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | qRT-PCR | NA | 0.72 | 0.5461 | 34163012 |
| NANOG | 20857 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | qRT-PCR and SFA | NA | 0.72 | 0.5461 | 33728488 |
| NANOG | 20857 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by qRT-PCR | NA | 0.72 | 0.5461 | 34446696 |
| NANOG | 20857 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | Migration and Invasion assay followed by RT-PCR and SFA | NA | 0.72 | 0.5461 | 30852389 |
| NANOG | 20857 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by qPCR | NA | 0.72 | 0.5461 | 32605166 |
| NANOG | 20857 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by qRT-PCR | NA | 0.72 | 0.5461 | 24521357 |
| NANOG | 20857 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by qRT-PCR | NA | 0.72 | 0.5461 | 26298849 |
| NANOG | 20857 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by qRT-PCR | NA | 0.72 | 0.5461 | 26439804 |
| NANOG | 20857 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by qRT-PCR | NA | 0.72 | 0.5461 | 26840266 |
| NANOG | 20857 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by qRT-PCR | NA | 0.72 | 0.5461 | 26918054 |
| NANOG | 20857 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by qRT-PCR | NA | 0.72 | 0.5461 | 27996162 |
| NANOG | 20857 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by qRT-PCR | NA | 0.72 | 0.5461 | 28580169 |
| NANOG | 20857 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by qRT-PCR | NA | 0.72 | 0.5461 | 30045656 |
| NANOG | 20857 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by qRT-PCR | NA | 0.72 | 0.5461 | 30954649 |
| NANOG | 20857 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by qRT-PCR | NA | 0.72 | 0.5461 | 31027735 |
| POU5F1 | 7553 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | Western Blotting and qRT-PCR | NA | 0.72 | 0.6448 | 28775772 |
| POU5F1 | 9221 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and qRT-PCR followed by Western Blotting and IF staining | NA | 0.72 | 0.6448 | 29975934 |
| POU5F1 | 9221 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | Gemcitabine | SFA followed by qRT-PCR and Western Blotting | NA | 0.72 | 0.6448 | 35158144 |
| POU5F1 | 9221 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | Gemcitabine | qRT-PCR followed by Western Blotting | NA | 0.72 | 0.6448 | 28703793 |
| POU5F1 | 9221 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.72 | 0.6448 | 27996162 |
| POU5F1 | 9221 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.72 | 0.6448 | 29937934 |
| POU5F1 | 9221 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by RT-PCR and Western Blotting | NA | 0.72 | 0.6448 | 23872274 |
| POU5F1 | 9221 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by RT-PCR and Western Blotting | NA | 0.72 | 0.6448 | 24305593 |
| POU5F1 | 9221 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SP assay followed by qRT-PCR and Western Blotting | NA | 0.72 | 0.6448 | 24040121 |
| POU5F1 | 9221 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | Gemcitabine | qRT-PCR followed by IHC staining | NA | 0.72 | 0.6448 | 23026911 |
| POU5F1 | 9221 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | FACs followed by qRT-PCR | NA | 0.72 | 0.6448 | 29444383 |
| POU5F1 | 9221 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | FACs followed by SFA and qPCR | NA | 0.72 | 0.6448 | 30954649 |
| POU5F1 | 9221 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | FACs followed by SFA and qRT-PCR | NA | 0.72 | 0.6448 | 29444383 |
| POU5F1 | 9221 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and Western Blotting | NA | 0.72 | 0.6448 | 35428310 |
| POU5F1 | 9221 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Western Blotting | NA | 0.72 | 0.6448 | 34551785 |
| POU5F1 | 9221 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | Western Blotting | NA | 0.72 | 0.6448 | 33708436 |
| POU5F1 | 9221 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | Gemcitabine | CFA followed by Western Blotting | NA | 0.72 | 0.6448 | 25015789 |
| POU5F1 | 9221 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | Gemcitabine | SFA followed by Western Blotting | NA | 0.72 | 0.6448 | 30341797 |
| POU5F1 | 9221 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | Gemcitabine | SFA followed by Western Blotting | NA | 0.72 | 0.6448 | 30341797 |
| POU5F1 | 9221 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Western Blotting | NA | 0.72 | 0.6448 | 30535490 |
| POU5F1 | 9221 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Western Blotting | NA | 0.72 | 0.6448 | 32766132 |
| POU5F1 | 9221 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | Western Blotting | NA | 0.72 | 0.6448 | 29179494 |
| POU5F1 | 9221 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | Western Blotting followed by SFA | NA | 0.72 | 0.6448 | 30819221 |
| POU5F1 | 9221 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by IF staining | NA | 0.72 | 0.6448 | 33915247 |
| POU5F1 | 9221 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | qRT-PCR | NA | 0.72 | 0.6448 | 34163012 |
| POU5F1 | 9221 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | qRT-PCR and SFA | NA | 0.72 | 0.6448 | 33728488 |
| POU5F1 | 9221 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and qRT-PCR | NA | 0.72 | 0.6448 | 35241126 |
| POU5F1 | 9221 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by qRT-PCR | NA | 0.72 | 0.6448 | 34446696 |
| POU5F1 | 9221 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | Modified transwell lower chamber assay and SFA followed by qRT-PCR | NA | 0.72 | 0.6448 | 24689055 |
| POU5F1 | 9221 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | 5-fluorouracil | qRT-PCR followed by SFA | NA | 0.72 | 0.6448 | 22993328 |
| POU5F1 | 9221 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by qPCR | NA | 0.72 | 0.6448 | 32605166 |
| POU5F1 | 9221 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by qRT-PCR | NA | 0.72 | 0.6448 | 24521357 |
| POU5F1 | 9221 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by qRT-PCR | NA | 0.72 | 0.6448 | 26298849 |
| POU5F1 | 9221 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by qRT-PCR | NA | 0.72 | 0.6448 | 26840266 |
| POU5F1 | 9221 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by qRT-PCR | NA | 0.72 | 0.6448 | 27505247 |
| POU5F1 | 9221 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by qRT-PCR | NA | 0.72 | 0.6448 | 27996162 |
| POU5F1 | 9221 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by qRT-PCR | NA | 0.72 | 0.6448 | 29434962 |
| POU5F1 | 9221 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by qRT-PCR | NA | 0.72 | 0.6448 | 30045656 |
| POU5F1 | 9221 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by qRT-PCR | NA | 0.72 | 0.6448 | 30954649 |
| POU5F1 | 9221 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by qRT-PCR | NA | 0.72 | 0.6448 | 31027735 |
| POU5F1 | 9221 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | Gemcitabine | SFA followed by qRT-PCR | NA | 0.72 | 0.6448 | 31508487 |
| POU5F1 | 9221 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | FACs followed by SP assay | NA | 0.72 | 0.6448 | 23815678 |
| POU5F1 | 9221 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by FACs | NA | 0.72 | 0.6448 | 26689865 |
| SOX2 | 11195 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and qRT-PCR followed by Western Blotting and IF staining | NA | 0.72 | 0.5695 | 29975934 |
| SOX2 | 11195 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | Gemcitabine | SFA followed by qRT-PCR and Western Blotting | NA | 0.72 | 0.5695 | 35158144 |
| SOX2 | 11195 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | Gemcitabine | qRT-PCR followed by Western Blotting | NA | 0.72 | 0.5695 | 28703793 |
| SOX2 | 11195 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | Gemcitabine | SFA followed by qRT-PCR and Western Blotting | NA | 0.72 | 0.5695 | 31508487 |
| SOX2 | 11195 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SP assay followed by qRT-PCR and Western Blotting | NA | 0.72 | 0.5695 | 24040121 |
| SOX2 | 11195 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | FACs followed by qRT-PCR | NA | 0.72 | 0.5695 | 29444383 |
| SOX2 | 11195 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | FACs followed by SFA and qPCR | NA | 0.72 | 0.5695 | 30954649 |
| SOX2 | 11195 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and Western Blotting | NA | 0.72 | 0.5695 | 35428310 |
| SOX2 | 11195 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Western Blotting | NA | 0.72 | 0.5695 | 33115754 |
| SOX2 | 11195 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Western Blotting | NA | 0.72 | 0.5695 | 34551785 |
| SOX2 | 11195 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | Western Blotting | NA | 0.72 | 0.5695 | 33708436 |
| SOX2 | 11195 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | Gemcitabine | CFA followed by Western Blotting | NA | 0.72 | 0.5695 | 25015789 |
| SOX2 | 11195 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Western Blotting | NA | 0.72 | 0.5695 | 26458814 |
| SOX2 | 11195 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | Gemcitabine | SFA followed by Western Blotting | NA | 0.72 | 0.5695 | 30341797 |
| SOX2 | 11195 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | Gemcitabine | SFA followed by Western Blotting | NA | 0.72 | 0.5695 | 30341797 |
| SOX2 | 11195 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Western Blotting | NA | 0.72 | 0.5695 | 30535490 |
| SOX2 | 11195 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Western Blotting | NA | 0.72 | 0.5695 | 32766132 |
| SOX2 | 11195 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | Western Blotting | NA | 0.72 | 0.5695 | 29179494 |
| SOX2 | 11195 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | Gemcitabine | Western Blotting followed by SFA | NA | 0.72 | 0.5695 | 30486896 |
| SOX2 | 11195 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | qRT-PCR | NA | 0.72 | 0.5695 | 34163012 |
| SOX2 | 11195 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by qRT-PCR | NA | 0.72 | 0.5695 | 34446696 |
| SOX2 | 11195 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | Migration and Invasion assay followed by RT-PCR and SFA | NA | 0.72 | 0.5695 | 30852389 |
| SOX2 | 11195 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | qRT-PCR | NA | 0.72 | 0.5695 | 30272287 |
| SOX2 | 11195 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | 5-fluorouracil | qRT-PCR followed by SFA | NA | 0.72 | 0.5695 | 22993328 |
| SOX2 | 11195 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by qPCR | NA | 0.72 | 0.5695 | 32605166 |
| SOX2 | 11195 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by qRT-PCR | NA | 0.72 | 0.5695 | 26298849 |
| SOX2 | 11195 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by qRT-PCR | NA | 0.72 | 0.5695 | 26439804 |
| SOX2 | 11195 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by qRT-PCR | NA | 0.72 | 0.5695 | 26840266 |
| SOX2 | 11195 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by qRT-PCR | NA | 0.72 | 0.5695 | 27505247 |
| SOX2 | 11195 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by qRT-PCR | NA | 0.72 | 0.5695 | 28580169 |
| SOX2 | 11195 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by qRT-PCR | NA | 0.72 | 0.5695 | 29434962 |
| SOX2 | 11195 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by qRT-PCR | NA | 0.72 | 0.5695 | 30954649 |
| SOX2 | 11195 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by qRT-PCR | NA | 0.72 | 0.5695 | 31027735 |
| SOX2 | 11195 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | FACs followed by SP assay | NA | 0.72 | 0.5695 | 23815678 |
| ALDH1A1 | 402 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and IF staining followed by FACs and qRT-PCR | NA | 0.56 | 0.684 | 28580169 |
| ALDH1A1 | 402 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by RT-PCR and Western Blotting | NA | 0.56 | 0.684 | 30802827 |
| ALDH1A1 | 402 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by RT-PCR and Western Blotting | NA | 0.56 | 0.684 | 30802827 |
| ALDH1A1 | 402 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SP assay followed by qRT-PCR and Western Blotting | NA | 0.56 | 0.684 | 24040121 |
| ALDH1A1 | 402 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | FACs followed by qRT-PCR | NA | 0.56 | 0.684 | 29444383 |
| ALDH1A1 | 402 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and Western Blotting | NA | 0.56 | 0.684 | 35428310 |
| ALDH1A1 | 402 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Western Blotting | NA | 0.56 | 0.684 | 33359649 |
| ALDH1A1 | 402 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | Gemcitabine | CFA followed by Western Blotting | NA | 0.56 | 0.684 | 25015789 |
| ALDH1A1 | 402 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Western Blotting | NA | 0.56 | 0.684 | 26458814 |
| ALDH1A1 | 402 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Western Blotting | NA | 0.56 | 0.684 | 28802012 |
| ALDH1A1 | 402 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | Western Blotting | NA | 0.56 | 0.684 | 29179494 |
| ALDH1A1 | 402 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | ALDEFLUOR assay and FACs followed by SFA | NA | 0.56 | 0.684 | 24489910 |
| ALDH1A1 | 402 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | FACs followed by ALDEFLUOR assay | NA | 0.56 | 0.684 | 29656202 |
| ALDH1A1 | 402 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | FACs followed by ALDEFLUOR assay | NA | 0.56 | 0.684 | 30954649 |
| ALDH1A1 | 402 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | Migration and Invasion assay followed by RT-PCR and SFA | NA | 0.56 | 0.684 | 30852389 |
| ALDH1A1 | 402 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | Gemcitabine | qPCR | NA | 0.56 | 0.684 | 31440741 |
| ALDH1A1 | 402 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by qRT-PCR | NA | 0.56 | 0.684 | 26918054 |
| ALDH1A1 | 402 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by qRT-PCR | NA | 0.56 | 0.684 | 29975934 |
| ALDH1A1 | 402 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | Gemcitabine | SFA followed by qRT-PCR | NA | 0.56 | 0.684 | 31508487 |
| ALDH1A1 | 402 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | ALDEFLUOR assay followed by CFA | NA | 0.56 | 0.684 | 32550888 |
| ALDH1A1 | 402 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | ALDEFLUOR assay followed by SFA | NA | 0.56 | 0.684 | 34551785 |
| ALDH1A1 | 402 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | ALDEFLUOR assay | NA | 0.56 | 0.684 | 21062983 |
| ALDH1A1 | 402 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | ALDEFLUOR assay | NA | 0.56 | 0.684 | 24575144 |
| ALDH1A1 | 402 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | ALDEFLUOR assay | NA | 0.56 | 0.684 | 28864067 |
| ALDH1A1 | 402 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | ALDEFLUOR assay | NA | 0.56 | 0.684 | 31312365 |
| ALDH1A1 | 402 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | ALDEFLUOR assay | NA | 0.56 | 0.684 | 31669811 |
| ALDH1A1 | 402 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | ALDEFLUOR assay followed by SFA | NA | 0.56 | 0.684 | 27748818 |
| ALDH1A1 | 402 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | FACs followed by SFA | NA | 0.56 | 0.684 | 27748818 |
| ALDH1A1 | 402 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | FACs followed by SFA | NA | 0.56 | 0.684 | 27999190 |
| ALDH1A1 | 402 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by ALDEFLUOR assay | NA | 0.56 | 0.684 | 30954649 |
| ALDH1A1 | 402 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by FACs | NA | 0.56 | 0.684 | 26887043 |
| PROM1 | 9454 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and IF staining followed by FACs and qRT-PCR | NA | 0.56 | 0.7582 | 28580169 |
| PROM1 | 9454 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by RT-PCR and Western Blotting | NA | 0.56 | 0.7582 | 30802827 |
| PROM1 | 9454 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by RT-PCR and Western Blotting | NA | 0.56 | 0.7582 | 30802827 |
| PROM1 | 9454 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SP assay followed by qRT-PCR and Western Blotting | NA | 0.56 | 0.7582 | 24040121 |
| PROM1 | 9454 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | Gemcitabine | qRT-PCR followed by IHC staining | NA | 0.56 | 0.7582 | 23026911 |
| PROM1 | 9454 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | Western Blotting followed by FACs and SFA | NA | 0.56 | 0.7582 | 29179494 |
| PROM1 | 9454 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | MACs followed by IHC staining | NA | 0.56 | 0.7582 | 31595775 |
| PROM1 | 9454 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs followed by qRT-PCR | NA | 0.56 | 0.7582 | 35241126 |
| PROM1 | 9454 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Western Blotting | NA | 0.56 | 0.7582 | 33359649 |
| PROM1 | 9454 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | Western Blotting and SFA | NA | 0.56 | 0.7582 | 34349642 |
| PROM1 | 9454 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Western Blotting | NA | 0.56 | 0.7582 | 26458814 |
| PROM1 | 9454 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Western Blotting | NA | 0.56 | 0.7582 | 28802012 |
| PROM1 | 9454 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | Western Blotting | NA | 0.56 | 0.7582 | 29947365 |
| PROM1 | 9454 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | Western Blotting followed by SFA | NA | 0.56 | 0.7582 | 30819221 |
| PROM1 | 9454 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by IF staining | NA | 0.56 | 0.7582 | 33915247 |
| PROM1 | 9454 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by IF staining | NA | 0.56 | 0.7582 | 26709750 |
| PROM1 | 9454 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by qRT-PCR | NA | 0.56 | 0.7582 | 34446696 |
| PROM1 | 9454 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | Migration and Invasion assay followed by RT-PCR and SFA | NA | 0.56 | 0.7582 | 30852389 |
| PROM1 | 9454 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | Gemcitabine | qPCR | NA | 0.56 | 0.7582 | 31440741 |
| PROM1 | 9454 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | qRT-PCR | NA | 0.56 | 0.7582 | 24726912 |
| PROM1 | 9454 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | Gemcitabine | SFA followed by qRT-PCR | NA | 0.56 | 0.7582 | 27531902 |
| PROM1 | 9454 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by qRT-PCR | NA | 0.56 | 0.7582 | 29975934 |
| PROM1 | 9454 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | FACs | NA | 0.56 | 0.7582 | 33708436 |
| PROM1 | 9454 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | FACs | NA | 0.56 | 0.7582 | 34163012 |
| PROM1 | 9454 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by FACs | NA | 0.56 | 0.7582 | 33115754 |
| PROM1 | 9454 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | FACs followed by SFA | NA | 0.56 | 0.7582 | 22570653 |
| PROM1 | 9454 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | FACs followed by SFA | NA | 0.56 | 0.7582 | 27505247 |
| PROM1 | 9454 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | FACs followed by Tumorigenicity assay | NA | 0.56 | 0.7582 | 30774366 |
| PROM1 | 9454 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | Modified transwell lower chamber assay and SFA followed by FACs | NA | 0.56 | 0.7582 | 24689055 |
| PROM1 | 9454 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by FACs | NA | 0.56 | 0.7582 | 22923052 |
| PROM1 | 9454 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by FACs | NA | 0.56 | 0.7582 | 24305593 |
| PROM1 | 9454 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by FACs | NA | 0.56 | 0.7582 | 26284537 |
| PROM1 | 9454 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by FACs | NA | 0.56 | 0.7582 | 26689865 |
| PROM1 | 9454 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by FACs | NA | 0.56 | 0.7582 | 30045656 |
| ABCG2 | 74 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SP assay followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.1739 | 24040121 |
| ABCG2 | 74 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.1739 | 33934523 |
| ABCG2 | 74 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.1739 | 22923052 |
| ABCG2 | 74 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | Western Blotting followed by SFA | NA | 0.48 | 0.1739 | 30819221 |
| ABCG2 | 74 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.1739 | 26335012 |
| ABCG2 | 74 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | Gemcitabine | SFA followed by qRT-PCR | NA | 0.48 | 0.1739 | 31508487 |
| ABCG2 | 74 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SP assay followed by qRT-PCR | NA | 0.48 | 0.1739 | 18240351 |
| ABCG2 | 74 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SP assay followed by qRT-PCR | NA | 0.48 | 0.1739 | 19296540 |
| ABCG2 | 74 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SP assay followed by RT-PCR | NA | 0.48 | 0.1739 | 18240351 |
| ABCG2 | 74 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | Cisplatin | SFA followed by FACs | NA | 0.48 | 0.1739 | 34123574 |
| ABCG2 | 74 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | Gemcitabine | SFA followed by FACs | NA | 0.48 | 0.1739 | 34123574 |
| ABCG2 | 74 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | FACs | NA | 0.48 | 0.1739 | 22948659 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.456 | 29937934 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by RT-PCR and Western Blotting | NA | 0.48 | 0.456 | 30802827 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by RT-PCR and Western Blotting | NA | 0.48 | 0.456 | 30802827 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | Western Blotting followed by FACs and SFA | NA | 0.48 | 0.456 | 29179494 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | Western Blotting followed by FACs and SFA and Tumorigenicity assay | NA | 0.48 | 0.456 | 28775772 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | FACs followed by IHC staining and SFA | NA | 0.48 | 0.456 | 31510100 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | IHC staining followed by FACs | NA | 0.48 | 0.456 | 30272287 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by FACs and qRT-PCR | NA | 0.48 | 0.456 | 29975934 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by SP assay and Western Blotting | NA | 0.48 | 0.456 | 23864708 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.456 | 26673007 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | Gemcitabine | Western Blotting followed by SFA | NA | 0.48 | 0.456 | 30486896 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | Microplate array followed by IF staining | NA | 0.48 | 0.456 | 23815678 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by IF staining | NA | 0.48 | 0.456 | 26709750 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | Modified transwell lower chamber assay and SFA followed by qRT-PCR | NA | 0.48 | 0.456 | 24689055 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | Gemcitabine | qPCR | NA | 0.48 | 0.456 | 31440741 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | Gemcitabine | qRT-PCR | NA | 0.48 | 0.456 | 23026911 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | qRT-PCR | NA | 0.48 | 0.456 | 24726912 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.456 | 29434962 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.456 | 31027735 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | Gemcitabine | SFA followed by qRT-PCR | NA | 0.48 | 0.456 | 31508487 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | FACs | NA | 0.48 | 0.456 | 33011221 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | FACs followed by SFA | NA | 0.48 | 0.456 | 34551785 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by FACs | NA | 0.48 | 0.456 | 33835973 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by FACs | NA | 0.48 | 0.456 | 33934523 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by FACs | NA | 0.48 | 0.456 | 34885233 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | FACs | NA | 0.48 | 0.456 | 22948659 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | FACs | NA | 0.48 | 0.456 | 26261532 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | FACs | NA | 0.48 | 0.456 | 26398277 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | FACs | NA | 0.48 | 0.456 | 27734340 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | FACs | NA | 0.48 | 0.456 | 27764163 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | FACs | NA | 0.48 | 0.456 | 28864067 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | FACs | NA | 0.48 | 0.456 | 29697746 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | FACs followed by Migration and Invasion assay | NA | 0.48 | 0.456 | 22335271 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | FACs followed by SFA | NA | 0.48 | 0.456 | 22570653 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | FACs followed by SFA | NA | 0.48 | 0.456 | 24521357 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | FACs followed by SFA | NA | 0.48 | 0.456 | 25852272 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | FACs followed by SFA | NA | 0.48 | 0.456 | 27748818 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | FACs followed by SFA | NA | 0.48 | 0.456 | 27748818 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | FACs followed by SFA | NA | 0.48 | 0.456 | 27999190 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | Doxycycline | FACs followed by SFA | NA | 0.48 | 0.456 | 28984401 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | FACs followed by SFA | NA | 0.48 | 0.456 | 29656202 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | FACs followed by SFA | NA | 0.48 | 0.456 | 29727019 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | FACs followed by SFA | NA | 0.48 | 0.456 | 32351328 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | FACs followed by SFA and Tumorigenicity assay | NA | 0.48 | 0.456 | 23872274 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | FACs followed by SP assay | NA | 0.48 | 0.456 | 23815678 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | FACs followed by Tumorigenicity assay | NA | 0.48 | 0.456 | 22111082 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and SP assay followed by FACs | NA | 0.48 | 0.456 | 29985062 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by FACs | NA | 0.48 | 0.456 | 23815678 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | Gemcitabine | SFA followed by FACs | NA | 0.48 | 0.456 | 25117811 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by FACs | NA | 0.48 | 0.456 | 26689865 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by FACs | NA | 0.48 | 0.456 | 26918054 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by FACs | NA | 0.48 | 0.456 | 28984791 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SP assay followed by FACs | NA | 0.48 | 0.456 | 30819221 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by RT-PCR and Western Blotting | NA | 0.48 | 1 | 30802827 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by RT-PCR and Western Blotting | NA | 0.48 | 1 | 30802827 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | Western Blotting followed by FACs and SFA | NA | 0.48 | 1 | 29179494 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | FACs followed by IHC staining and SFA | NA | 0.48 | 1 | 31510100 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | IHC staining followed by FACs | NA | 0.48 | 1 | 30272287 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | FACs followed by qRT-PCR | NA | 0.48 | 1 | 29444383 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by FACs and qRT-PCR | NA | 0.48 | 1 | 29975934 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by qRT-PCR and FACs | NA | 0.48 | 1 | 23917223 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by qRT-PCR and FACs | NA | 0.48 | 1 | 26439804 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and Western Blotting | NA | 0.48 | 1 | 35428310 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Western Blotting | NA | 0.48 | 1 | 33359649 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | Western Blotting and SFA | NA | 0.48 | 1 | 34349642 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by SP assay and Western Blotting | NA | 0.48 | 1 | 23864708 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Western Blotting | NA | 0.48 | 1 | 26458814 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Western Blotting | NA | 0.48 | 1 | 26673007 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Western Blotting | NA | 0.48 | 1 | 27996162 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Western Blotting | NA | 0.48 | 1 | 28802012 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Western Blotting | NA | 0.48 | 1 | 32395477 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | Western Blotting | NA | 0.48 | 1 | 29947365 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by IF staining | NA | 0.48 | 1 | 33915247 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | Microplate array followed by IF staining | NA | 0.48 | 1 | 23815678 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by IF staining | NA | 0.48 | 1 | 26709750 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | Gemcitabine | qPCR | NA | 0.48 | 1 | 31440741 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | Gemcitabine | qRT-PCR | NA | 0.48 | 1 | 23026911 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | qRT-PCR | NA | 0.48 | 1 | 24726912 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by qRT-PCR | NA | 0.48 | 1 | 26335012 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by qRT-PCR | NA | 0.48 | 1 | 26840266 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by qRT-PCR | NA | 0.48 | 1 | 27996162 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by qRT-PCR | NA | 0.48 | 1 | 28580169 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by qRT-PCR | NA | 0.48 | 1 | 29434962 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by qRT-PCR | NA | 0.48 | 1 | 31027735 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | FACs | NA | 0.48 | 1 | 33011221 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | FACs | NA | 0.48 | 1 | 33708436 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | FACs and SFA | NA | 0.48 | 1 | 33728488 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | FACs followed by CFA | NA | 0.48 | 1 | 34556996 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | FACs followed by SFA | NA | 0.48 | 1 | 34551785 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by FACs | NA | 0.48 | 1 | 33835973 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by FACs | NA | 0.48 | 1 | 33934523 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by FACs | NA | 0.48 | 1 | 34885233 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | FACs | NA | 0.48 | 1 | 22948659 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | FACs | NA | 0.48 | 1 | 26261532 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | FACs | NA | 0.48 | 1 | 26398277 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | FACs | NA | 0.48 | 1 | 27734340 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | FACs | NA | 0.48 | 1 | 27764163 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | FACs | NA | 0.48 | 1 | 28864067 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | FACs | NA | 0.48 | 1 | 29201179 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | FACs | NA | 0.48 | 1 | 29697746 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | FACs and CFA followed by SFA and Tumorigenicity assay | NA | 0.48 | 1 | 25849939 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | FACs followed by Migration and Invasion assay | NA | 0.48 | 1 | 22335271 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | FACs followed by SFA | NA | 0.48 | 1 | 22570653 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | FACs followed by SFA | NA | 0.48 | 1 | 24521357 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | FACs followed by SFA | NA | 0.48 | 1 | 25852272 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | FACs followed by SFA | NA | 0.48 | 1 | 27748818 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | FACs followed by SFA | NA | 0.48 | 1 | 27748818 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | FACs followed by SFA | NA | 0.48 | 1 | 27999190 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | FACs followed by SFA | NA | 0.48 | 1 | 28507102 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | Doxycycline | FACs followed by SFA | NA | 0.48 | 1 | 28984401 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | FACs followed by SFA | NA | 0.48 | 1 | 29656202 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | FACs followed by SFA | NA | 0.48 | 1 | 29727019 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | FACs followed by SFA | NA | 0.48 | 1 | 29937934 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | FACs followed by SFA | NA | 0.48 | 1 | 32351328 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | FACs followed by SP assay | NA | 0.48 | 1 | 23815678 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | FACs followed by Tumorigenicity assay | NA | 0.48 | 1 | 22111082 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | Modified transwell lower chamber assay and SFA followed by FACs | NA | 0.48 | 1 | 24689055 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and SP assay followed by FACs | NA | 0.48 | 1 | 29985062 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by FACs | NA | 0.48 | 1 | 23815678 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by FACs | NA | 0.48 | 1 | 23872274 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | Gemcitabine | SFA followed by FACs | NA | 0.48 | 1 | 25117811 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by FACs | NA | 0.48 | 1 | 25502497 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by FACs | NA | 0.48 | 1 | 26689865 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by FACs | NA | 0.48 | 1 | 26918054 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by FACs | NA | 0.48 | 1 | 28984791 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SP assay followed by FACs | NA | 0.48 | 1 | 30819221 |
| GLI1 | 4317 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.0308 | 22923052 |
| GLI1 | 4317 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.0308 | 29697746 |
| GLI1 | 4317 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by RT-PCR | NA | 0.48 | 0.0308 | 26918054 |
| GLI2 | 4318 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.0106 | 22923052 |
| GLI2 | 4318 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.0106 | 29697746 |
| GPSM2 | 29501 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | qRT-PCR and Western Blotting | NA | 0.48 | 0.0021 | 30774366 |
| HSF1 | 5224 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | Gemcitabine | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.0032 | 35158144 |
| LIN28A | 15986 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | Gemcitabine | qRT-PCR followed by Western Blotting | NA | 0.48 | 0.0138 | 28703793 |
| LIN28A | 15986 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.0138 | 27996162 |
| MYC | 7553 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by RT-PCR and Western Blotting | NA | 0.48 | 0.1304 | 24305593 |
| MYC | 7553 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SP assay followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.1304 | 24040121 |
| MYC | 7553 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.1304 | 29975934 |
| MYC | 7553 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.1304 | 30535490 |
| MYC | 7553 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | qRT-PCR | NA | 0.48 | 0.1304 | 34163012 |
| MYC | 7553 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | qRT-PCR | NA | 0.48 | 0.1304 | 30272287 |
| MYC | 7553 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.1304 | 26298849 |
| NOTCH1 | 7881 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SP assay followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.0477 | 24040121 |
| NOTCH1 | 7881 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | Gemcitabine | CFA followed by Western Blotting | NA | 0.48 | 0.0477 | 25015789 |
| PIM3 | 9221 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | Western Blotting and qRT-PCR | NA | 0.48 | 0.0011 | 28775772 |
| SKI | 10896 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | qPCR followed by Western Blotting | NA | 0.48 | 0.0021 | 27734340 |
| SMO | 11119 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.0212 | 22923052 |
| SMO | 11119 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.0212 | 29697746 |
| SMO | 11119 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by RT-PCR | NA | 0.48 | 0.0212 | 26918054 |
| EPCAM | 11529 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | Western Blotting followed by FACs and SFA and Tumorigenicity assay | NA | 0.4 | 0.211 | 28775772 |
| EPCAM | 11529 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | FACs followed by IHC staining and SFA | NA | 0.4 | 0.211 | 31510100 |
| EPCAM | 11529 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | IHC staining followed by FACs | NA | 0.4 | 0.211 | 30272287 |
| EPCAM | 11529 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by FACs and qRT-PCR | NA | 0.4 | 0.211 | 29975934 |
| EPCAM | 11529 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by qRT-PCR and FACs | NA | 0.4 | 0.211 | 26439804 |
| EPCAM | 11529 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Western Blotting | NA | 0.4 | 0.211 | 26673007 |
| EPCAM | 11529 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Western Blotting | NA | 0.4 | 0.211 | 27996162 |
| EPCAM | 11529 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | Microplate array followed by IF staining | NA | 0.4 | 0.211 | 23815678 |
| EPCAM | 11529 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by IF staining | NA | 0.4 | 0.211 | 26709750 |
| EPCAM | 11529 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by qRT-PCR | NA | 0.4 | 0.211 | 34446696 |
| EPCAM | 11529 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | Modified transwell lower chamber assay and SFA followed by qRT-PCR | NA | 0.4 | 0.211 | 24689055 |
| EPCAM | 11529 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | Gemcitabine | qPCR | NA | 0.4 | 0.211 | 31440741 |
| EPCAM | 11529 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | Gemcitabine | qRT-PCR | NA | 0.4 | 0.211 | 23026911 |
| EPCAM | 11529 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by qRT-PCR | NA | 0.4 | 0.211 | 27996162 |
| EPCAM | 11529 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | Gemcitabine | SFA followed by qRT-PCR | NA | 0.4 | 0.211 | 31508487 |
| EPCAM | 11529 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | FACs and SFA | NA | 0.4 | 0.211 | 33728488 |
| EPCAM | 11529 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | FACs followed by CFA | NA | 0.4 | 0.211 | 34556996 |
| EPCAM | 11529 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by FACs | NA | 0.4 | 0.211 | 33835973 |
| EPCAM | 11529 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by FACs | NA | 0.4 | 0.211 | 34885233 |
| EPCAM | 11529 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | FACs | NA | 0.4 | 0.211 | 22948659 |
| EPCAM | 11529 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | FACs | NA | 0.4 | 0.211 | 26261532 |
| EPCAM | 11529 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | FACs | NA | 0.4 | 0.211 | 26398277 |
| EPCAM | 11529 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | FACs | NA | 0.4 | 0.211 | 27764163 |
| EPCAM | 11529 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | FACs | NA | 0.4 | 0.211 | 28864067 |
| EPCAM | 11529 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | FACs and CFA followed by SFA and Tumorigenicity assay | NA | 0.4 | 0.211 | 25849939 |
| EPCAM | 11529 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | FACs followed by SFA | NA | 0.4 | 0.211 | 22570653 |
| EPCAM | 11529 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | FACs followed by SFA | NA | 0.4 | 0.211 | 24521357 |
| EPCAM | 11529 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | FACs followed by SFA | NA | 0.4 | 0.211 | 27999190 |
| EPCAM | 11529 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | Doxycycline | FACs followed by SFA | NA | 0.4 | 0.211 | 28984401 |
| EPCAM | 11529 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | FACs followed by SFA | NA | 0.4 | 0.211 | 29656202 |
| EPCAM | 11529 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | FACs followed by SFA | NA | 0.4 | 0.211 | 29727019 |
| EPCAM | 11529 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | FACs followed by SFA | NA | 0.4 | 0.211 | 29937934 |
| EPCAM | 11529 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | FACs followed by SFA | NA | 0.4 | 0.211 | 32351328 |
| EPCAM | 11529 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | FACs followed by SFA and Tumorigenicity assay | NA | 0.4 | 0.211 | 23872274 |
| EPCAM | 11529 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | FACs followed by SP assay | NA | 0.4 | 0.211 | 23815678 |
| EPCAM | 11529 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and SP assay followed by FACs | NA | 0.4 | 0.211 | 29985062 |
| EPCAM | 11529 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by FACs | NA | 0.4 | 0.211 | 23815678 |
| EPCAM | 11529 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by FACs | NA | 0.4 | 0.211 | 25502497 |
| EPCAM | 11529 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by FACs | NA | 0.4 | 0.211 | 26918054 |
| ADM | 259 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.36 | 0.0032 | 27746256 |
| CTSD | 2529 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.36 | 0.0053 | 27746256 |
| HNRNPA2B1 | 4718 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.36 | 0.0042 | 27746256 |
| HSPA5 | 5238 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.36 | 0.0117 | 27746256 |
| ITGB1 | 6153 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.36 | 0.018 | 27746256 |
| LGALS3 | 6563 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.36 | 0.0021 | 27746256 |
| MARCKS | 6759 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.36 | 0.0032 | 27746256 |
| ME1 | 6983 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.36 | 0.0042 | 27746256 |
| VCL | 12665 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.36 | 0.0032 | 27746256 |
| VIM | 12692 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.36 | 0.017 | 27746256 |
| YWHAE | 12851 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.36 | 0.0021 | 27746256 |
| YWHAZ | 12855 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.36 | 0.0042 | 27746256 |
| ADM | 259 | HTM/LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics and Western Blotting | Up | 0.36 | 0.0032 | 27746256 |
| CP | 2295 | HTM/LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics and Western Blotting | Up | 0.36 | 0.0021 | 26850699 |
| CTSD | 2529 | HTM/LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics and Western Blotting | Down | 0.36 | 0.0053 | 27746256 |
| HNRNPA2B1 | 5033 | HTM/LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics and Western Blotting | Down | 0.36 | 0.0042 | 27746256 |
| HSPA5 | 5238 | HTM/LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics and Western Blotting | Down | 0.36 | 0.0117 | 27746256 |
| ITGB1 | 6153 | HTM/LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics and Western Blotting | Down | 0.36 | 0.018 | 27746256 |
| LGALS1 | 6561 | HTM/LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics and Western Blotting | Down | 0.36 | 0.0053 | 27746256 |
| LGALS3 | 6563 | HTM/LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics and Western Blotting | Up | 0.36 | 0.0021 | 26850699 |
| MARCKS | 6759 | HTM/LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics and Western Blotting | Up | 0.36 | 0.0032 | 26850699 |
| MARCKS | 6759 | HTM/LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics and Western Blotting | Up | 0.36 | 0.0032 | 27746256 |
| ME1 | 6983 | HTM/LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics and Western Blotting | Up | 0.36 | 0.0042 | 27746256 |
| PGK1 | 8896 | HTM/LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics and Western Blotting | Up | 0.36 | 0.0032 | 27746256 |
| PGK1 | 8896 | HTM/LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics and Western Blotting | Up | 0.36 | 0.0032 | 27746256 |
| VCL | 12665 | HTM/LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics and Western Blotting | Up | 0.36 | 0.0032 | 27746256 |
| VIM | 12692 | HTM/LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics and Western Blotting | Down | 0.36 | 0.017 | 27746256 |
| YWHAE | 12851 | HTM/LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics and Western Blotting | Up | 0.36 | 0.0021 | 27746256 |
| YWHAZ | 12855 | HTM/LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics and Western Blotting | Up | 0.36 | 0.0042 | 27746256 |
| NES | 7756 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.32 | 0.0573 | 27746256 |
| ABCG2- | 74 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | FACs followed by qRT-PCR | NA | 0.32 | 0.0011 | 29444383 |
| NES | 7756 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | FACs followed by qRT-PCR | NA | 0.32 | 0.0573 | 29444383 |
| NES | 7756 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | Western Blotting | NA | 0.32 | 0.0573 | 29947365 |
| NES | 7756 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | Western Blotting followed by SFA | NA | 0.32 | 0.0573 | 30819221 |
| NES | 7756 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by IF staining | NA | 0.32 | 0.0573 | 26709750 |
| NES | 7756 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | Gemcitabine | qPCR | NA | 0.32 | 0.0573 | 31440741 |
| NES | 7756 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by qRT-PCR | NA | 0.32 | 0.0573 | 26335012 |
| NES | 7756 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | Gemcitabine | SFA followed by qRT-PCR | NA | 0.32 | 0.0573 | 27531902 |
| NES | 7756 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by qRT-PCR | NA | 0.32 | 0.0573 | 29434962 |
| NES | 7756 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by qRT-PCR | NA | 0.32 | 0.0573 | 31027735 |
| NES | 7756 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by FACs | NA | 0.32 | 0.0573 | 26689865 |
| THY1 | 11801 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | FACs followed by SFA and qPCR | NA | 0.32 | 0.0371 | 30954649 |
| THY1 | 11801 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by qRT-PCR and FACs and Tumorigenicity assay | NA | 0.32 | 0.0371 | 30954649 |
| KRT19 | 6436 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.28 | 0.0074 | 27746256 |
| ACVR1 | 171 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | Western Blotting followed by SFA | NA | 0.28 | 0.0011 | 30819221 |
| BMI1 | 1066 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.1135 | 33115754 |
| BMI1 | 1066 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.1135 | 28802012 |
| BMI1 | 1066 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | Western Blotting | NA | 0.28 | 0.1135 | 23815678 |
| BMI1 | 1066 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | Gemcitabine | Western Blotting followed by SFA | NA | 0.28 | 0.1135 | 30486896 |
| FAM83A | 28210 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | Western Blotting followed by SFA and SP assay and Tumorigenicity assay | NA | 0.28 | 0.0011 | 28287611 |
| FOXM1 | 3818 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0053 | 28802012 |
| FZD7 | 4045 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0064 | 33934523 |
| GLI3 | 4319 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0021 | 29697746 |
| GPX4 | 4556 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | Western Blotting and SFA followed by Migration and Invasion assay | NA | 0.28 | 0.0021 | 30535490 |
| KRT19 | 6436 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | Western Blotting followed by SFA | NA | 0.28 | 0.0074 | 30819221 |
| MET | 7029 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | Western Blotting and SFA | NA | 0.28 | 0.0191 | 34349642 |
| MET | 7029 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | Migration and Invasion assay followed by qRT-PCR | NA | 0.28 | 0.0191 | 23592398 |
| MET | 7029 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | FACs followed by SFA | NA | 0.28 | 0.0191 | 26298849 |
| PTCH1 | 9585 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0032 | 29697746 |
| SHH | 10848 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0201 | 29697746 |
| SHH | 10848 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by RT-PCR | NA | 0.28 | 0.0201 | 26918054 |
| SOX9 | 11204 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0244 | 28984791 |
| SOX9 | 11204 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | Gemcitabine | Migration and Invasion assay followed by qRT-PCR and SFA | NA | 0.28 | 0.0244 | 23592398 |
| STAT3 | 11364 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and Western Blotting | NA | 0.28 | 0.0223 | 27748818 |
| TSPAN8 | 11855 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0032 | 32395477 |
| WNT7B | 12787 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0042 | 33934523 |
| MIR148B | 31761 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.24 | 0.0021 | 25117811 |
| MIR32 | 31631 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.24 | 0.0042 | 25117811 |
| MIR320A | 31632 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Transcriptomics | Down | 0.24 | 0.0021 | 28580169 |
| MIR370 | 31784 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.24 | 0.0021 | 25117811 |
| MIR378A | 31871 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.24 | 0.0053 | 25117811 |
| MIR378C | 38374 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.24 | 0.0021 | 25117811 |
| MIR486-1 | 32342 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.24 | 0.0053 | 25117811 |
| MIR1-1 | 31499 | HTM/LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0021 | 29975934 |
| MIR127 | 31509 | HTM/LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0042 | 29975934 |
| MIR134 | 31519 | HTM/LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0021 | 29975934 |
| MIR148A | 31535 | HTM/LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0021 | 29975934 |
| MIR148B | 31761 | HTM/LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0021 | 29975934 |
| MIR185 | 31556 | HTM/LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0021 | 29975934 |
| MIR193A | 31563 | HTM/LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0042 | 29975934 |
| MIR20A | 31577 | HTM/LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0042 | 29975934 |
| MIR3182 | 38317 | HTM/LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0011 | 29975934 |
| MIR32 | 31631 | HTM/LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0042 | 29975934 |
| MIR320A | 31632 | HTM/LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0021 | 29975934 |
| MIR340 | 31777 | HTM/LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0011 | 29975934 |
| MIR370 | 31784 | HTM/LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0021 | 29975934 |
| MIR374A | 31788 | HTM/LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0021 | 29975934 |
| MIR377 | 31870 | HTM/LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0021 | 29975934 |
| MIR378A | 31871 | HTM/LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0053 | 29975934 |
| MIR378C | 38374 | HTM/LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0021 | 29975934 |
| MIR411 | 32792 | HTM/LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0011 | 29975934 |
| MIR486-1 | 32342 | HTM/LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0053 | 29975934 |
| MIR889 | 33651 | HTM/LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0011 | 29975934 |
| ABCB1 | 40 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | Gemcitabine | SFA followed by qRT-PCR | NA | 0.2 | 0.0604 | 31508487 |
| ABCB1 | 40 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SP assay followed by qRT-PCR | NA | 0.2 | 0.0604 | 18240351 |
| ABCB1 | 40 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SP assay followed by RT-PCR | NA | 0.2 | 0.0604 | 18240351 |
| ABCB1 | 40 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | Cisplatin | SFA followed by FACs | NA | 0.2 | 0.0604 | 34123574 |
| ABCB1 | 40 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | Gemcitabine | SFA followed by FACs | NA | 0.2 | 0.0604 | 34123574 |
| CTNNB1 | 2514 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | qRT-PCR | NA | 0.2 | 0.0647 | 30272287 |
| CXCR4 | 2561 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | Migration and Invasion assay followed by qRT-PCR | NA | 0.2 | 0.0498 | 23592398 |
| CXCR4 | 2561 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | Gemcitabine | qPCR | NA | 0.2 | 0.0498 | 31440741 |
| CXCR4 | 2561 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | Gemcitabine | SFA followed by qRT-PCR | NA | 0.2 | 0.0498 | 31508487 |
| DCLK1 | 2700 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | Gemcitabine | qPCR | NA | 0.2 | 0.0159 | 31440741 |
| DCLK1 | 2700 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by FACs | NA | 0.2 | 0.0159 | 26673007 |
| HSPA6 | 5239 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | Gemcitabine | SFA followed by qRT-PCR | NA | 0.2 | 0.0053 | 35158144 |
| HSPE1 | 5269 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | Gemcitabine | SFA followed by qRT-PCR | NA | 0.2 | 0.0053 | 35158144 |
| HSPH1 | 16969 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | Gemcitabine | SFA followed by qRT-PCR | NA | 0.2 | 0.0021 | 35158144 |
| KLF4 | 6348 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | qRT-PCR | NA | 0.2 | 0.0891 | 34163012 |
| KLF4 | 6348 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.0891 | 26298849 |
| KLF4 | 6348 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | Gemcitabine | SFA followed by qRT-PCR | NA | 0.2 | 0.0891 | 31508487 |
| LGR5 | 4504 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | Gemcitabine | SFA followed by qRT-PCR | NA | 0.2 | 0.0753 | 27531902 |
| LINC-ROR | 43773 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.0021 | 28580169 |
| MIR135B | 31760 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | qRT-PCR | NA | 0.2 | 0.0032 | 32351328 |
| NR5A2 | 7984 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.0042 | 27996162 |
| STK11 | 11389 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.0032 | 28507102 |
| ABCB5 | 46 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | Gemcitabine | SFA followed by FACs | NA | 0.12 | 0.0085 | 34123574 |
| ABCC1 | 51 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | Cisplatin | SFA followed by FACs | NA | 0.12 | 0.0212 | 34123574 |
| ABCC1 | 51 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | Gemcitabine | SFA followed by FACs | NA | 0.12 | 0.0212 | 34123574 |
| CALR | 1455 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by FACs | NA | 0.12 | 0.0032 | 33835973 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | FACs | NA | 0.12 | 0.456 | 29201179 |
| 6PGD | 12757 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 27746256 |
| A2M | 7 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0032 | 27746256 |
| ACAT1 | 93 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0021 | 27746256 |
| ACLY | 115 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 27746256 |
| ACTN4 | 166 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0074 | 27746256 |
| AHCY | 343 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 27746256 |
| AHNAK | 347 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0042 | 27746256 |
| AHNAK2 | 20125 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0021 | 27746256 |
| AIFM1 | 8768 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0042 | 27746256 |
| ALDOA | 414 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0042 | 27746256 |
| ANPEP | 500 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0117 | 27746256 |
| ANXA1 | 533 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0053 | 27746256 |
| ANXA11 | 535 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0021 | 27746256 |
| ANXA5 | 543 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 27746256 |
| ARL3 | 694 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 27746256 |
| ATP5F1B | 830 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0021 | 27746256 |
| BASP1 | 957 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0042 | 27746256 |
| BCAP31 | 8768 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0032 | 27746256 |
| BOLA2 | 29488 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0021 | 27746256 |
| BSG | 1116 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0021 | 27746256 |
| BZW1 | 18380 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 27746256 |
| CALM1 | 442 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0021 | 27746256 |
| CAP1 | 20040 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0032 | 27746256 |
| CAV1 | 1527 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0117 | 27746256 |
| CAVIN1 | 9688 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0032 | 27746256 |
| CCN2 | 2500 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0021 | 27746256 |
| CCT2 | 1615 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0032 | 27746256 |
| CCT3 | 1616 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0032 | 27746256 |
| CCT4 | 1617 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0032 | 27746256 |
| CCT5 | 1618 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0021 | 27746256 |
| CCT8 | 1623 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 27746256 |
| CD109 | 21685 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0053 | 27746256 |
| CD59 | 1689 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0032 | 27746256 |
| CES1 | 28817 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0032 | 27746256 |
| CFL1 | 1874 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0042 | 27746256 |
| CH10 | 21637 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0011 | 27746256 |
| CLIC1 | 2062 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0042 | 27746256 |
| CNDP2 | 24437 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 27746256 |
| COPA | 2230 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0021 | 27746256 |
| COPB | 2231 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 27746256 |
| COTL1 | 18304 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0032 | 27746256 |
| COX5A | 2267 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0032 | 27746256 |
| CPT1A | 2328 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0011 | 27746256 |
| CREBBP | 2348 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0021 | 27746256 |
| CS | 2422 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0021 | 27746256 |
| CSE1L | 2431 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0032 | 27746256 |
| CYTB | 7427 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 27746256 |
| DBN1 | 2695 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0021 | 27746256 |
| DCTN2 | 2712 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 27746256 |
| DDX18 | 2741 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0021 | 27746256 |
| DDX21 | 2744 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0021 | 27746256 |
| DHX9 | 2750 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0053 | 27746256 |
| DKK3 | 2893 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0042 | 27746256 |
| DYNC1H1 | 2961 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0032 | 27746256 |
| EEF1A1 | 3189 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0032 | 27746256 |
| EEF1B2 | 3208 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0042 | 27746256 |
| EEF2 | 3214 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0053 | 27746256 |
| EF1G | 3213 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 27746256 |
| EFHD2 | 28670 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0032 | 27746256 |
| EGFR | 3236 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0074 | 27746256 |
| EIF4A1 | 3282 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0042 | 27746256 |
| EIF4G1 | 3296 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0021 | 27746256 |
| EIF5A | 3300 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0042 | 27746256 |
| ENO1 | 3350 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0095 | 27746256 |
| EPRS1 | 3418 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 27746256 |
| ESYT1 | 29534 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0032 | 27746256 |
| EZR | 12691 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0064 | 27746256 |
| FAS | 11920 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0032 | 27746256 |
| FH | 3700 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0042 | 27746256 |
| FHL1 | 3702 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0021 | 27746256 |
| FSCN1 | 11148 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0064 | 27746256 |
| FUBP1 | 4004 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0042 | 27746256 |
| G6PD | 4057 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0032 | 27746256 |
| GART | 4163 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0064 | 27746256 |
| GCN1L | 4199 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 27746256 |
| GLO1 | 4323 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0042 | 27746256 |
| GSTO1 | 13312 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0021 | 27746256 |
| H1-2 | 4716 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0053 | 27746256 |
| H1-4 | 1863 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0011 | 27746256 |
| H2AX | 4739 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0011 | 27746256 |
| H3C14 | 20503 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0011 | 27746256 |
| H4-16 | 20510 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0011 | 27746256 |
| HADHA | 4801 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0042 | 27746256 |
| HEXB | 4879 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0021 | 27746256 |
| HNRNPA3 | 5033 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0032 | 27746256 |
| HNRNPAB | 11316 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0032 | 27746256 |
| HNRNPC | 5035 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0032 | 27746256 |
| HNRNPH3 | 5043 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0021 | 27746256 |
| HNRNPK | 5044 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0021 | 27746256 |
| HNRNPL | 5045 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0011 | 27746256 |
| HNRNPM | 5046 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0021 | 27746256 |
| HNRNPU | 5048 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0042 | 27746256 |
| HNRPF | 5039 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0011 | 27746256 |
| HP1BP3 | 24973 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0032 | 27746256 |
| HSP90AA1 | 5253 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0064 | 27746256 |
| HSP90AB1 | 5258 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0074 | 27746256 |
| HSPA8 | 5241 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0085 | 27746256 |
| HSPA9 | 5244 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0042 | 27746256 |
| HSPB1 | 5246 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0053 | 27746256 |
| HSPD1 | 5261 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0064 | 27746256 |
| HYOU1 | 16931 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0042 | 27746256 |
| ICAM1 | 5344 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0064 | 27746256 |
| IDH2 | 5383 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0021 | 27746256 |
| IGF2BP3 | 28868 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0032 | 27746256 |
| IGFBP7 | 5476 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0042 | 27746256 |
| ILF3 | 6038 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0021 | 27746256 |
| IPO7 | 9852 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 27746256 |
| IQGAP1 | 6110 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0042 | 27746256 |
| ITGA2 | 6137 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0106 | 27746256 |
| ITGA3 | 6139 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0032 | 27746256 |
| KHDRBS1 | 18116 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0021 | 27746256 |
| KHSRP | 6316 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0032 | 27746256 |
| KLK3 | 6364 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0021 | 27746256 |
| KRT18 | 6430 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0074 | 27746256 |
| KRT2 | 6439 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0021 | 27746256 |
| KTN1 | 6467 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0032 | 27746256 |
| LDHA | 6535 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0053 | 27746256 |
| LDHB | 6541 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0042 | 27746256 |
| LEG1 | 20960 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0011 | 27746256 |
| LGALS3BP | 6564 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0042 | 27746256 |
| LMNA | 6636 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0042 | 27746256 |
| LMNB2 | 6638 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0021 | 27746256 |
| LRPPRC | 15714 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0064 | 27746256 |
| LRRC59 | 8091 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0021 | 27746256 |
| LTA4H | 6710 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0021 | 27746256 |
| MACsROH2A1 | 4740 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0021 | 27746256 |
| MATR3 | 6912 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0032 | 27746256 |
| MCM7 | 6950 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0032 | 27746256 |
| MDH1 | 6970 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0053 | 27746256 |
| MDH2 | 6971 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0021 | 27746256 |
| MKI67 | 7107 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0021 | 27746256 |
| MTHFD1 | 7432 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0032 | 27746256 |
| MVP | 7531 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0042 | 27746256 |
| MX1 | 7532 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0032 | 27746256 |
| MYBBP1A | 1689 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0032 | 27746256 |
| MYH9 | 7579 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0064 | 27746256 |
| MYL12A | 16701 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0032 | 27746256 |
| MYL6 | 7587 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0021 | 27746256 |
| MYOF | 3656 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0032 | 27746256 |
| NAP1L1 | 7637 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0032 | 27746256 |
| NCL | 24941 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0042 | 27746256 |
| NOLC1 | 15608 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0042 | 27746256 |
| NONO | 7871 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0021 | 27746256 |
| NPM1 | 7910 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0042 | 27746256 |
| OAT | 8091 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0042 | 27746256 |
| OPA6 | 33170 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0011 | 27746256 |
| PAK2 | 8591 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0021 | 27746256 |
| PARK7 | 16369 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0021 | 27746256 |
| PARP1 | 270 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0021 | 27746256 |
| PFN1 | 8881 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0042 | 27746256 |
| PGAM1 | 8888 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0042 | 27746256 |
| PGM1 | 8905 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0021 | 27746256 |
| PHB | 8912 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0032 | 27746256 |
| PHB2 | 30306 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0021 | 27746256 |
| PKM | 9021 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0032 | 27746256 |
| PLEC | 9069 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0053 | 27746256 |
| PPIA | 9253 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 27746256 |
| PRDX1 | 9352 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0042 | 27746256 |
| PRDX5 | 9355 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0032 | 27746256 |
| PRDX6 | 16753 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0042 | 27746256 |
| PRKDC | 9413 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0032 | 27746256 |
| PSMC3 | 9549 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 27746256 |
| PSMC4 | 9551 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0032 | 27746256 |
| PSME1 | 9568 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0032 | 27746256 |
| PTBP1 | 9583 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0011 | 27746256 |
| PYGB | 9723 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0021 | 27746256 |
| RAP1B | 9857 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0011 | 27746256 |
| RARS1 | 9870 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0021 | 27746256 |
| RBM25 | 23244 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0021 | 27746256 |
| RPL31 | 10334 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0021 | 27746256 |
| RPN1 | 10381 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0042 | 27746256 |
| RS3 | 20367 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 27746256 |
| RSL1D1 | 24534 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0021 | 27746256 |
| S100A11 | 10488 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0042 | 27746256 |
| S100A6 | 10496 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0053 | 27746256 |
| SERPINE1 | 8583 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0053 | 27746256 |
| SF3B2 | 10769 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0011 | 27746256 |
| SFPQ | 10774 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0042 | 27746256 |
| SH2D1A | 10820 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0011 | 27746256 |
| SH3BGRL3 | 15568 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0032 | 27746256 |
| SINHCAF | 30702 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0032 | 27746256 |
| SLC16A3 | 10924 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0021 | 27746256 |
| SLC25A5 | 10991 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0032 | 27746256 |
| SLC3A2 | 11026 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0085 | 27746256 |
| SLC7A5 | 11063 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0042 | 27746256 |
| SMU1 | 18247 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0011 | 27746256 |
| SNX3 | 11174 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 27746256 |
| SOD1 | 11179 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0032 | 27746256 |
| SRRT | 24101 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0011 | 27746256 |
| SRSF1 | 10780 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0021 | 27746256 |
| SSB | 7546 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0011 | 27746256 |
| ST13 | 11343 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0021 | 27746256 |
| STIP1 | 11387 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0042 | 27746256 |
| SYNCRIP | 16918 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0053 | 27746256 |
| TBX20 | 11598 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0021 | 27746256 |
| TCP1 | 11655 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0053 | 27746256 |
| TGM2 | 11778 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0032 | 27746256 |
| THIC | NA | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 27746256 |
| THRAP3 | 22964 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0011 | 27746256 |
| TIMM44 | 17316 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0011 | 27746256 |
| TIMM50 | 23656 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0021 | 27746256 |
| TKT | 11834 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0053 | 27746256 |
| TPI1 | 12009 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0042 | 27746256 |
| TPI1 | 12009 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0042 | 27746256 |
| TPM4 | 12013 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0053 | 27746256 |
| TRIM28 | 16384 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0021 | 27746256 |
| TUFM | 12420 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0042 | 27746256 |
| TXN | 12435 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0021 | 27746256 |
| UBA1 | 12469 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0042 | 27746256 |
| WDR1 | 12754 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 27746256 |
| XRCC5 | 12833 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0032 | 27746256 |
| XRCC6 | 4055 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0053 | 27746256 |
| YARS1 | 12840 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 27746256 |
| ZYX | 13200 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0021 | 27746256 |
| MIR101-1 | 31488 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 25117811 |
| MIR106A | 31494 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 25117811 |
| MIR1202 | 35268 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 25117811 |
| MIR1226 | 33922 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 25117811 |
| MIR1228 | 33928 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 25117811 |
| MIR1228 | 33928 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 25117811 |
| MIR1234 | 33926 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 25117811 |
| MIR1236 | 33925 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 25117811 |
| MIR1237 | 33927 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 25117811 |
| MIR1246 | 35312 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 25117811 |
| MIR1249 | 35315 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 25117811 |
| MIR1260B | 38258 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 25117811 |
| MIR1268A | 35336 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 25117811 |
| MIR1273C | 38173 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 25117811 |
| MIR1280 | 35368 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 25117811 |
| MIR128-1 | 31510 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 28580169 |
| MIR1288 | 35363 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 25117811 |
| MIR1290 | 35283 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 25117811 |
| MIR130A | 31514 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 25117811 |
| MIR132 | 31516 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 25117811 |
| MIR1343 | 41902 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 25117811 |
| MIR141 | 31528 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 25117811 |
| MIR145 | 31532 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 28580169 |
| MIR1469 | 35378 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 25117811 |
| MIR146A | 31533 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0042 | 25117811 |
| MIR147B | 33655 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 25117811 |
| MIR155 | 31542 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0053 | 25117811 |
| MIR15B | 31544 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0085 | 25117811 |
| MIR17 | 31547 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 25117811 |
| MIR181A2 | 31549 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 25117811 |
| MIR181d | 32089 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 25117811 |
| MIR1825 | 35389 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 25117811 |
| MIR188 | 31559 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 25117811 |
| MIR1908 | 35392 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 25117811 |
| MIR191 | 31561 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 25117811 |
| MIR1913 | 35397 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 25117811 |
| MIR1914 | 35398 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 25117811 |
| MIR1915 | 35399 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 25117811 |
| MIR193B | 32087 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 25117811 |
| MIR196B | 31790 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 25117811 |
| MIR1972-1 | 37060 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 25117811 |
| MIR19B1 | 31575 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 25117811 |
| MIR200A | 31578 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 25117811 |
| MIR200B | 31579 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 25117811 |
| MIR200C | 31580 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0074 | 25117811 |
| MIR20B | 32024 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 25117811 |
| MIR21 | 31586 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0085 | 25117811 |
| MIR210 | 31587 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0064 | 25117811 |
| MIR218-1 | 31595 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 25117811 |
| MIR221 | 31601 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0053 | 25117811 |
| MIR224 | 31604 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0042 | 25117811 |
| MIR2355 | 38328 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 25117811 |
| MIR2467 | 41881 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 25117811 |
| MIR2861 | 38221 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 25117811 |
| MIR29A | 31616 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0053 | 25117811 |
| MIR29B1 | 31619 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0064 | 25117811 |
| MIR29B1 | 31619 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0064 | 25117811 |
| MIR301A | 31622 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 25117811 |
| MIR3065 | 38234 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 25117811 |
| MIR30A | 31624 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0085 | 25117811 |
| MIR30d | 31628 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 25117811 |
| MIR30e | 31629 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 25117811 |
| MIR31 | 31630 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0064 | 25117811 |
| MIR3130-1 | 38275 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 25117811 |
| MIR3131 | 38347 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 25117811 |
| MIR3141 | 38326 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 25117811 |
| MIR3147 | 38300 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 25117811 |
| MIR3154 | 38176 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 25117811 |
| MIR3173 | 38174 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 25117811 |
| MIR3178 | 38381 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 25117811 |
| MIR3180-1 | 38382 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 25117811 |
| MIR3184 | 38182 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 25117811 |
| MIR3187 | 38319 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 25117811 |
| MIR3188 | 38226 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 25117811 |
| MIR3193 | 38204 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 25117811 |
| MIR3194 | 38346 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 25117811 |
| MIR3195 | 38250 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 25117811 |
| MIR3200 | 38227 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 25117811 |
| MIR320B | NA | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 28580169 |
| MIR323A | 31766 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 25117811 |
| MIR324 | 31767 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 25117811 |
| MIR324 | 31767 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 25117811 |
| MIR328 | 31770 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 25117811 |
| MIR330 | 31771 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 25117811 |
| MIR338 | 31775 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 25117811 |
| MIR339 | 31776 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 25117811 |
| MIR33A | 31634 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 25117811 |
| MIR345 | 31779 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 25117811 |
| MIR346 | 31780 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 25117811 |
| MIR361 | 31867 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 25117811 |
| MIR3619 | 38998 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 25117811 |
| MIR362 | 32022 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 25117811 |
| MIR3621 | 38930 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 25117811 |
| MIR3665 | 38939 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 25117811 |
| MIR3682 | 38916 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 25117811 |
| MIR371A | 31785 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 25117811 |
| MIR378D1 | 41550 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 25117811 |
| MIR378E | 41671 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 25117811 |
| MIR378F | 41686 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 25117811 |
| MIR378G | 41785 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 25117811 |
| MIR378I | 41620 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 25117811 |
| MIR3917 | 38911 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 25117811 |
| MIR3937 | 38970 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 25117811 |
| MIR3940 | 38893 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 25117811 |
| MIR3960 | 41595 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 25117811 |
| MIR421 | 32793 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 25117811 |
| MIR422A | 31879 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 25117811 |
| MIR423 | 31880 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 25117811 |
| MIR424 | 31881 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0064 | 25117811 |
| MIR425 | 31882 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 25117811 |
| MIR425 | 31882 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 25117811 |
| MIR4257 | 38312 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 25117811 |
| MIR4258 | 38281 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 25117811 |
| MIR4261 | 38272 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 25117811 |
| MIR4279 | 38195 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 25117811 |
| MIR4284 | 38322 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 25117811 |
| MIR4288 | 38203 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 25117811 |
| MIR429 | 13784 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 25117811 |
| MIR4319 | 38212 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 25117811 |
| MIR4428 | 41667 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 25117811 |
| MIR4455 | 41536 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 25117811 |
| MIR4463 | 41665 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 25117811 |
| MIR4465 | 41842 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 25117811 |
| MIR4466 | 41726 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 25117811 |
| MIR4467 | 41896 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 25117811 |
| MIR4476 | 41793 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 25117811 |
| MIR4484 | 41799 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 25117811 |
| MIR4485 | 41628 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 25117811 |
| MIR4487 | 41851 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 25117811 |
| MIR4488 | 41599 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 25117811 |
| MIR4492 | 41563 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 25117811 |
| MIR4497 | 41737 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 25117811 |
| MIR449B | 32794 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 25117811 |
| MIR4508 | 41659 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 25117811 |
| MIR4516 | 41617 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 25117811 |
| MIR451A | 32053 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 28580169 |
| MIR4530 | 41764 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 25117811 |
| MIR4535 | 41629 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 25117811 |
| MIR4638 | 41841 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 25117811 |
| MIR4646 | 41543 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 25117811 |
| MIR4655 | 41754 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 25117811 |
| MIR4665 | 41696 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 25117811 |
| MIR4669 | 41558 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 25117811 |
| MIR4674 | 41729 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 25117811 |
| MIR4675 | 41619 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 25117811 |
| MIR4685 | 41802 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 25117811 |
| MIR4685 | 41802 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 25117811 |
| MIR4687 | 41712 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 25117811 |
| MIR4687 | 41712 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 25117811 |
| MIR4689 | 41895 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 25117811 |
| MIR4697 | 41570 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 25117811 |
| MIR4706 | 41576 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 25117811 |
| MIR4707 | 41531 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 25117811 |
| MIR4713 | 41899 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 25117811 |
| MIR4716 | 41812 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 25117811 |
| MIR4721 | 41609 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 25117811 |
| MIR4725 | 41608 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 25117811 |
| MIR4731 | 41597 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 25117811 |
| MIR4732 | 41639 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 25117811 |
| MIR4739 | 41801 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 25117811 |
| MIR4745 | 41868 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 25117811 |
| MIR4749 | 41760 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 25117811 |
| MIR4750 | 41765 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 25117811 |
| MIR4758 | 41836 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 25117811 |
| MIR4783 | 41874 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 25117811 |
| MIR4787 | 41653 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 25117811 |
| MIR4787 | 41653 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 25117811 |
| MIR483 | 32340 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0053 | 25117811 |
| MIR484 | 32341 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 25117811 |
| MIR487B | 32533 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 25117811 |
| MIR491 | 32076 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 25117811 |
| MIR500A | 32134 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 25117811 |
| MIR500A | 32134 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 25117811 |
| MIR500B | 38223 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 25117811 |
| MIR518B | 32106 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 25117811 |
| MIR532 | 32795 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 25117811 |
| MIR532 | 32795 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 25117811 |
| MIR557 | 32813 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 25117811 |
| MIR590 | 32846 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 25117811 |
| MIR593 | 32849 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 25117811 |
| MIR614 | 32870 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 25117811 |
| MIR615 | 32871 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 25117811 |
| MIR622 | 32878 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 25117811 |
| MIR624 | 32880 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 25117811 |
| MIR629 | 32885 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 25117811 |
| MIR658 | 32914 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 25117811 |
| MIR660 | 32916 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 25117811 |
| MIR663A | 32919 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 25117811 |
| MIR665 | 33662 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 25117811 |
| MIR670 | 37304 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 25117811 |
| MIR671 | 33134 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 25117811 |
| MIR675 | 33351 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 25117811 |
| MIR7-1 | 31638 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 25117811 |
| MIR7-1 | 31638 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 28580169 |
| MIR718 | 37317 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 25117811 |
| MIR720 | NA | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 25117811 |
| MIR7-3HG | 30049 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 28580169 |
| MIR762 | 37303 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 25117811 |
| MIR766 | 33139 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 25117811 |
| MIR873 | 33663 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 25117811 |
| MIR874 | 33643 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 25117811 |
| MIR887 | 33661 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 25117811 |
| MIR920 | 33670 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 25117811 |
| MIR921 | 33671 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 25117811 |
| MIR92B | 32920 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 25117811 |
| MIR93 | 31645 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 28580169 |
| MIR93 | 31645 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 28580169 |
| MIR939 | 33682 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 25117811 |
| MIR940 | 33683 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 25117811 |
| MIR96 | 31648 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 25117811 |
| MIR98 | 31649 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 28580169 |
| MIRLET7A1 | 31476 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 28580169 |
| MIRLET7A1 | 31476 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 28580169 |
| MIRLET7B | 31479 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 28580169 |
| MIRLET7B | 31479 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 28580169 |
| MIRLET7C | 31480 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 28580169 |
| MIRLET7C | 31480 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 28580169 |
| MIRLET7D | 31481 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 28580169 |
| MIRLET7D | 31481 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 28580169 |
| MIRLET7E | 31482 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 28580169 |
| MIRLET7E | 31482 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 28580169 |
| MIRLET7F1 | 31483 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0053 | 25117811 |
| MIRLET7F1 | 31483 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 28580169 |
| MIRLET7F1 | 31483 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 28580169 |
| MIRLET7F2 | 31484 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 28580169 |
| MIRLET7G | 31485 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 28580169 |
| MIRLET7G | 31485 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 28580169 |
| MIRLET7I | 31486 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 25117811 |
| MIRLET7I | 31486 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 28580169 |
| MIRLET7I | 31486 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 28580169 |
| SNORD111B | 33579 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 25117811 |
| SNORD138 | 50420 | HTM | Pancreatic Cancer | Carcinoma | PANC-1 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 25117811 |